CD4 (CD4 Molecule)

P2, N=50, Enrolling by invitation, SWOG Cancer Research Network | Not yet recruiting --> Enrolling by invitation

This study aimed to investigate the combined use of ACD and TP (paclitaxel and cisplatin) against non-small cell lung cancer (NSCLC) in a orthotopic mouse model. In conclusion, the combination of ACD plus TP demonstrated potent anti-tumor and immunomodulation effects against NSCLC in association with reduced Treg activity and increased CD8+ T cell infiltration. Our study provides compelling preclinical evidence supporting ACD as an immunomodulatory adjunct to conventional NSCLC therapies.

Collectively, our findings demonstrate that HY-oAd can enhance intratumoral accumulation of 177Lu-aPD-L1 in a multifaceted manner to elicit synergistic antitumor immune response against desmoplastic and poorly immunogenic pancreatic tumors.

While overall immune infiltration was comparable between HR-deficient and proficient tumors, terminally exhausted CD8 and conventional CD4 T cells were enriched in HR-deficient tumors, where their presence correlated with improved progression-free survival. These findings suggest that exhausted T cells may indicate protective immunity even outside the context of immunotherapy and underscore their prognostic relevance in solid tumors.

P2, N=39, Active, not recruiting, Alliance Foundation Trials, LLC. | Trial completion date: Mar 2026 --> Aug 2026 | Trial primary completion date: Mar 2026 --> Nov 2025

P1, N=20, Recruiting, National Institute of Allergy and Infectious Diseases (NIAID) | Trial completion date: Mar 2026 --> Mar 2027 | Trial primary completion date: Mar 2026 --> Mar 2027

This 10-fraction whole-breast radiotherapy regimen was acceptable. These findings support this regimen as a practical alternative for adjuvant breast radiotherapy.

Early recognition is essential to avoid unnecessary treatments, guide supportive care, and enable timely referral for advanced therapies. Clinicians should consider SIOD in patients presenting with short stature and nephrotic syndrome to optimize outcomes.

Downregulation of IL16 also reduced cell viability and decreased the IC50 of cytarabine (Ara-C) across different concentrations...High IL16 expression was observed in malignant cells from patients with AML. Downregulation of IL16 promotes degradation of mutant TP53 and induces apoptosis, thereby increasing the sensitivity of AML cells to various chemotherapeutic agents in vitro.

Circ-PVT1 is upregulated in CRC patients and encoded a novel protein: PVT1-104aa. PVT1-104aa promotes CRC progression and predicts worse prognosis. PVT1-104aa enhance Myc expression through inhibition of Myc ubiquitination. PVT1-104aa regulate PD-L1 expression of CRC cells and modulate T cells infiltration in vivo.

Reduced collagen deposition in HAS2⁺/⁻ tumors further underscores its role in tumor microenvironment remodeling. Targeting the HAS2-March4-PD-L1 axis through HAS2 inhibition, anti-PD-L1 therapy, or March4 overexpression suppresses tumor growth and improves survival.

Importantly, nHA-Mn demonstrates potent tumor growth suppression and induces immune memory T cell formation while maintaining excellent biosafety profiles in vivo. Hence, this study establishes a broadly applicable therapeutic platform that uniquely integrates direct tumor cytotoxicity with self-adjuvanting immune activation, highlighting the promising potential of rational metal ion engineering in advancing next-generation cancer immunotherapy.